The FDA approved a series of newly designed cardiac devices from Medtronic that helps to minimize hospitalization for patients. Included in the line of devices to treat heart failure are the Viva cardiac resynchronization therapy with defibrillation CRT-D and the Evera implantable cardioverter-defibrillators (ICD).
Trial data showed that the Viva CRT-D improved the response rate to therapy for patients diagnosed with heart failure. Heart failure hospitalizations showed a decrease by 21 percent. The device now has the ability to adapt to an individual patient's needs and preserve the normal rhythm of the heart. The response rate to CRT-D therapy among heart-failure patients was improved by 12 percent as a result of the algorithm known as AdapticCRT.
The new, contoured design of the Viva CRT-D and Evera defibrillation devices reduced skin pressure by 30 percent and delivered longer battery power.
"These devices offer patients and physicians advanced systems that can improve patients' overall quality of life, while reducing the cost burdens of unnecessary hospitalizations. Patients can now experience a more comfortable fit, due to less skin pressure, a longer lasting battery, and highly advanced CRT-D algorithms," Dr. Jagmeet P. Singh said in a press release. Singh is the director of the resynchronization and advanced cardiac therapeutics program at Massachusetts General Hospital in Boston.
Medtronic partners with clinicians, researchers and scientists all over the world to develop a range innovative medical technology. These products are made specifically to treat heart failure and offer interventional and surgical solutions for heart disease and cardiac arrhythmias.
"These devices are designed to provide optimal therapy for patients, while providing economic benefits through fewer hospitalizations, fewer inappropriate shocks and increased longevity, which can result in lower healthcare costs. Patients suffering from debilitating heart rhythm disorders can rely on new treatment options that can significantly improve their quality of life," medical director for the Cardiac Rhythm Disease Management business at Medtronic, David Steinhaus, said.
